Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, D.-H. | - |
dc.contributor.author | Oh, I.-Y. | - |
dc.contributor.author | Lee, H.-Y. | - |
dc.contributor.author | Kim, Y.-J. | - |
dc.contributor.author | Kim, H.-S. | - |
dc.contributor.author | Kim, C.-H. | - |
dc.contributor.author | Oh, B.-H. | - |
dc.contributor.author | Kim, K.-S. | - |
dc.contributor.author | Kim, D.-I. | - |
dc.contributor.author | Kim, Y.-D. | - |
dc.contributor.author | Ryu, K.-H. | - |
dc.contributor.author | Park, S.-H. | - |
dc.contributor.author | Baek, S.-H. | - |
dc.contributor.author | Shin, D.-G. | - |
dc.contributor.author | Shim, W.J. | - |
dc.contributor.author | Ahn, T.-H. | - |
dc.contributor.author | Oh, S.-K. | - |
dc.contributor.author | Lee, S.-H. | - |
dc.contributor.author | Lee, S.-Y. | - |
dc.contributor.author | Jeong, M.-H. | - |
dc.contributor.author | Chung, W.-S. | - |
dc.contributor.author | Jeong, J.-Y. | - |
dc.contributor.author | Choi, S.-Y. | - |
dc.contributor.author | Choi, S.-W. | - |
dc.contributor.author | Hyon, M.-S. | - |
dc.date.accessioned | 2021-09-08T09:14:31Z | - |
dc.date.available | 2021-09-08T09:14:31Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/118290 | - |
dc.description.abstract | Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function. Copyright © 2010 The Korean Society of Cardiology. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | 2,4 thiazolidinedione derivative | - |
dc.subject | alpha glucosidase inhibitor | - |
dc.subject | antacid agent | - |
dc.subject | antilipemic agent | - |
dc.subject | antithrombocytic agent | - |
dc.subject | biguanide | - |
dc.subject | C reactive protein | - |
dc.subject | gelatinase B | - |
dc.subject | glyceryl trinitrate | - |
dc.subject | lacidipine | - |
dc.subject | monocyte chemotactic protein 1 | - |
dc.subject | oral antidiabetic agent | - |
dc.subject | plasminogen activator inhibitor 1 | - |
dc.subject | sulfonylurea | - |
dc.subject | adult | - |
dc.subject | artery endothelium | - |
dc.subject | article | - |
dc.subject | backache | - |
dc.subject | biochemistry | - |
dc.subject | bladder cancer | - |
dc.subject | blood level | - |
dc.subject | blood pressure | - |
dc.subject | blood pressure measurement | - |
dc.subject | borderline hypertension | - |
dc.subject | brain hemorrhage | - |
dc.subject | clinical trial | - |
dc.subject | depression | - |
dc.subject | diabetes mellitus | - |
dc.subject | diastolic blood pressure | - |
dc.subject | disease severity | - |
dc.subject | dizziness | - |
dc.subject | drug dose increase | - |
dc.subject | drug induced headache | - |
dc.subject | essential hypertension | - |
dc.subject | female | - |
dc.subject | heart palpitation | - |
dc.subject | hemorrhoid | - |
dc.subject | human | - |
dc.subject | hypoglycemia | - |
dc.subject | impaired glucose tolerance | - |
dc.subject | Korea | - |
dc.subject | larynx cancer | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | maximum permissible dose | - |
dc.subject | monocyte | - |
dc.subject | multicenter study | - |
dc.subject | outcome assessment | - |
dc.subject | prostate hypertrophy | - |
dc.subject | systolic blood pressure | - |
dc.subject | thorax pain | - |
dc.subject | treatment duration | - |
dc.subject | vasodilatation | - |
dc.title | Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shim, W.J. | - |
dc.identifier.doi | 10.4070/kcj.2010.40.12.632 | - |
dc.identifier.scopusid | 2-s2.0-79551696061 | - |
dc.identifier.bibliographicCitation | Korean Circulation Journal, v.40, no.12, pp.632 - 638 | - |
dc.relation.isPartOf | Korean Circulation Journal | - |
dc.citation.title | Korean Circulation Journal | - |
dc.citation.volume | 40 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 632 | - |
dc.citation.endPage | 638 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001530534 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | 2,4 thiazolidinedione derivative | - |
dc.subject.keywordPlus | alpha glucosidase inhibitor | - |
dc.subject.keywordPlus | antacid agent | - |
dc.subject.keywordPlus | antilipemic agent | - |
dc.subject.keywordPlus | antithrombocytic agent | - |
dc.subject.keywordPlus | biguanide | - |
dc.subject.keywordPlus | C reactive protein | - |
dc.subject.keywordPlus | gelatinase B | - |
dc.subject.keywordPlus | glyceryl trinitrate | - |
dc.subject.keywordPlus | lacidipine | - |
dc.subject.keywordPlus | monocyte chemotactic protein 1 | - |
dc.subject.keywordPlus | oral antidiabetic agent | - |
dc.subject.keywordPlus | plasminogen activator inhibitor 1 | - |
dc.subject.keywordPlus | sulfonylurea | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | artery endothelium | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | backache | - |
dc.subject.keywordPlus | biochemistry | - |
dc.subject.keywordPlus | bladder cancer | - |
dc.subject.keywordPlus | blood level | - |
dc.subject.keywordPlus | blood pressure | - |
dc.subject.keywordPlus | blood pressure measurement | - |
dc.subject.keywordPlus | borderline hypertension | - |
dc.subject.keywordPlus | brain hemorrhage | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | depression | - |
dc.subject.keywordPlus | diabetes mellitus | - |
dc.subject.keywordPlus | diastolic blood pressure | - |
dc.subject.keywordPlus | disease severity | - |
dc.subject.keywordPlus | dizziness | - |
dc.subject.keywordPlus | drug dose increase | - |
dc.subject.keywordPlus | drug induced headache | - |
dc.subject.keywordPlus | essential hypertension | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | heart palpitation | - |
dc.subject.keywordPlus | hemorrhoid | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hypoglycemia | - |
dc.subject.keywordPlus | impaired glucose tolerance | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | larynx cancer | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | maximum permissible dose | - |
dc.subject.keywordPlus | monocyte | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | prostate hypertrophy | - |
dc.subject.keywordPlus | systolic blood pressure | - |
dc.subject.keywordPlus | thorax pain | - |
dc.subject.keywordPlus | treatment duration | - |
dc.subject.keywordPlus | vasodilatation | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
dc.subject.keywordAuthor | Endothelium | - |
dc.subject.keywordAuthor | Hypertension | - |
dc.subject.keywordAuthor | Lacidipine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.